title: Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway.
abstract: Odanacatib is a potent cathespin K inhibitor that is being developed as a novel therapy for osteoporosis. The disposition and metabolism of odanacatib were evaluated in rats, dogs, and rhesus monkeys after intravenous and oral administration of [¹⁴C]odanacatib. Odanacatib was characterized by low systemic clearance in all species and by a long plasma half-life in monkeys (18 h) and dogs (64 h). The oral bioavailability was dependent on the vehicle used and ranged from 18% (monkey) to ~100% (dog) at doses of 1 to 5 mg/kg, using nonaqueous vehicles. After intravenous and oral administration to intact rats and monkeys > 90% of the dose was recovered, mainly in the feces. Studies in bile duct-cannulated animals indicated that biliary secretion was the major mode of elimination of radioactivity; odanacatib also underwent some intestinal secretion. In monkeys, odanacatib was almost completely eliminated by metabolism; metabolism also played a major role in the clearance of odanacatib in rats and dogs. The major metabolic pathways were methyl hydroxylation (formation of M8 and its derivatives), methyl sulfone demethylation (formation of M4 and its derivative M5), and glutathione conjugation (formation of the cyclized cysteinylglycine adduct M6 after addition of glutathione to the nitrile group of odanacatib). The major metabolites in rats [M4 (parent-14 Da) and M5 (oxygenated derivative of M4)] were determined to arise from a novel pathway that involved oxidative demethylation of the methylsulfonyl moiety of odanacatib. Overall, odanacatib displayed species-dependent metabolism, which explains, at least in part, the divergent plasma half-life observed.
authors.affiliation: Department of Drug Metabolism, WP75B-200, Merck Research Laboratories, P.O. Box 4, West Point, PA 19486, USA. kelem_kassahun@merck.com
authors.forename: Kelem
authors.initials: K
authors.lastname: Kassahun
authors.forename: W Cameron
authors.initials: WC
authors.lastname: Black
authors.forename: Deborah
authors.initials: D
authors.lastname: Nicoll-Griffith
authors.forename: Ian
authors.initials: I
authors.lastname: McIntosh
authors.forename: Nathalie
authors.initials: N
authors.lastname: Chauret
authors.forename: Stephen
authors.initials: S
authors.lastname: Day
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Rosenberg
authors.forename: Kenneth
authors.initials: K
authors.lastname: Koeplinger
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001713:Biphenyl Compounds / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics*; D056657:Cathepsin K / Q000037:antagonists & inhibitors*; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D007275:Injections, Intravenous; D008253:Macaca mulatta; D008297:Male; D013058:Mass Spectrometry; D008657:Metabolic Clearance Rate; D053858:Metabolic Networks and Pathways; D008745:Methylation; D015394:Molecular Structure; D051381:Rats; D017207:Rats, Sprague-Dawley; D013045:Species Specificity; D013450:Sulfones / Q000737:chemistry*
chemical_list: D001713:Biphenyl Compounds; D013450:Sulfones; D056657:Cathepsin K; C527128:odanacatib